ライフサイエンスコーパス: argon laser

1 xtrafoveal involvement and were treated with argon laser.

2 tion in C57BL/6 and Cd59a(-/-) mice using an argon laser.

3 etina of adult goldfish were ablated with an argon laser.

4 ore comfortable profile when compared to the argon laser.

5 mination provided by another output from the argon laser.

6 rt, noncoagulating heat pulse provided by an argon laser.

7 g an epicardial obstacle (2 x 10 mm) with an argon laser.

8 A blue-green (488-514 nm) argon laser activated the adhesive, and the strength of

9 Argon laser and selective laser trabeculoplasty are safe

10 The exact mechanisms by which argon laser and selective laser trabeculoplasty lower in

11 cuss the differences between the traditional argon laser and the PASCAL.

12 er photocoagulation in C57BL/6 mice using an argon laser, and the animals received rCD59-APT542 via i

13 diameter 0.8 microm) on the membrane with an Argon laser beam (488 nm) and following the fluorescence

14 may be one of the complications after FLACS. Argon laser cystotomy is effective in the management of

15 Four weeks later, argon laser cystotomy was performed, and the cyst disapp

16 s now being substituted for the conventional argon laser for PRP in many clinics.

17 fective than that performed with traditional argon laser in effecting lasting regression of retinal n

18 uding cataract extraction, paracentesis, and argon laser iridoplasty.

19 as elevated unilaterally in Wistar rats with argon laser irradiation of the trabecular meshwork 5 day

20 y, the authors used two different lasers--an argon laser (lambda = 458 nm) for stimuli and a low back

21 Three sizes of argon laser lesions designed to damage the outer retina

22 A 10 microm spot of argon laser light was focused onto the outer segments of

23 arboxyfluorescein (6-CF) dye and cut with an argon laser microbeam (lambda = 488 nm).

24 ation and reduction of neovascularization by argon laser pan-retinal photocoagulation successfully ma

25 othelial growth factor therapy (6 patients), argon laser photocoagulation (2 patients), intravitreal

26 Treatment (pre-PDT vs. PDT) included argon laser photocoagulation (42.1% vs. 0.4%), PDT (0% v

27 elevated unilaterally by repeated trabecular argon laser photocoagulation 5 days after intracameral i

28 steroids, nonsteroidal inflammatory agents, argon laser photocoagulation, and photodynamic therapy h

29 photography) and therapeutic interventions (argon laser photocoagulation, photodynamic therapy, intr

30 Anesthetized cats underwent retinal argon laser photocoagulation.

31 nal vein near the optic disc was occluded by argon laser radiation delivered through an optical fiber

32 Patients treated with the PASCAL and argon laser received a similar number of spots (1438 vs

33 A low-power argon laser (retinal power density of 5.7 W/cm2) locally

34 tungsten-halogen (QTH), plasma-arc (PAC), or argon laser sources in monolayer culture.

35 sured by spot photobleaching using a focused argon laser spot (488 nm).

36 The introduction of argon laser technology to clinical instruments is one ne

37 infants who had previously undergone retinal argon laser therapy of ROP.

38 /YFP) entails suboptimal donor excitation by Argon lasers, thereby hindering FRET imaging on many con

39 ch of 12 cynomolgus monkeys was treated with argon laser to the anterior chamber angle to induce elev

40 eral level I studies also found that SLT and argon laser trabeculoplasty (ALT) are equivalent in term

41 aser trabeculoplasty (SLT) was compared with argon laser trabeculoplasty (ALT) in a randomized clinic

42 3.14, P < 0.01, 95% CI, 1.91-5.17) and past argon laser trabeculoplasty (HR 1.81, P < 0.01, 95% CI,

43 escribe the proposed mechanisms of action of argon laser trabeculoplasty and selective laser trabecul

44 t interaction for the treatment sequences of argon laser trabeculoplasty and trabeculectomy, and that

45 dentification of risk factors for failure of argon laser trabeculoplasty and trabeculectomy, and the

46 mediate treatment with topical betaxolol and argon laser trabeculoplasty or to no initial treatment a

47 mized patients with early glaucoma either to argon laser trabeculoplasty plus betaxolol (n = 129) or

48 efficacy in patients with previously failed argon laser trabeculoplasty treatment.

49 ocular experimental glaucoma was produced by argon laser trabeculoplasty, and visual fields were asse

50 Argon laser trabeculoplasty, using typical clinical trea

51 trabeculoplasty may be a better option than argon laser trabeculoplasty.

52 the SLT a reasonable and safe alternative to argon laser trabeculoplasty.

53 ostaglandin analogues, topical steroids, and argon laser trabeculoplasty.

54 Argon laser treatment of the anterior chamber angle was

55 Argon laser treatment of the anterior chamber angle was

56 mental glaucoma was induced in 10 monkeys by argon laser treatment of the trabecular meshwork.

57 Argon laser treatment with selected use of anti-VEGF the

58 ed in the right eyes of 18 rhesus monkeys by argon laser treatments to the trabecular meshwork.

59 al experimental glaucoma that was induced by argon laser treatments to their trabecular meshwork.

60 At the end of the lens-rearing period, an argon laser was used to ablate the fovea in one eye of e

61 Light from an argon laser was used to resonantly excite the electronic

62 An argon laser with a beam diameter of 100 mum, exposure du

63 docyanine green angiography and treated with argon laser with and without anti-vascular endothelial g

64 th rose bengal dye and thermal burns from an argon laser with green light.